Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

In vivo Radiosensitization Effect of H DAC Inhibitor, SK-7041 on RIF-1 Cell Line

히스톤 탈아세틸효소 억제제 SK-7041의 RIF-1 세포주에 대한 생체내 방사선 감수성 증진 효과

  • Chie, Eui-Kyu (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Shin, Jin-Hee (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, In-Ah (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Il-Han (Department of Radiation Oncology, Seoul National University College of Medicine)
  • 지의규 (서울대학교 의과대학 방사선종양학교실) ;
  • 신진희 (서울대학교 의과대학 방사선종양학교실) ;
  • 김인아 (서울대학교 의과대학 방사선종양학교실) ;
  • 김일한 (서울대학교 의과대학 방사선종양학교실)
  • Received : 2010.08.25
  • Accepted : 2010.12.13
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To test the radiosensitizing effect of the newly synthesized novel histone deacetylase inhibitor, SK-7041 in vivo. Materials and Method: The RIF-l cell line was implanted into the back of a 6-week-old female C3H mouse, intradermally, The mice were grouped into control, drug, radiation (RT), and RT+drug group. SK-7041, 4 mg/kg was administered intraperitoneally for six cycles every 12 hours for mice in the drug and RT+drug group, An identical volume of phosphate buffered saline (PBS) was administered at the same frequency to mice in the control and RT groups. A single 5 Gy fraction was delivered to mice in RT and RT+drug group 6 hours after the fourth delivery. The volume of the implanted tumor was measured every 2~3 days to formulate the growth delay curve. Results: For the control, drug, RT, and RT +drug groups, the average duration for implanted tumor to reach a volume of $1,500mm^3$ was 10 days, 10 days, 9 days, and 12 days, respectively. Moreover, the tumor volume on D14 was $276.7mm^3$, $279.9mm^3$, $292.5mm^3$, and $185.5mm^3$, respectively (p=0.0004). The difference for the change in slope for the control and drug versus the RT and RT+drug groups were borderline significant (p=0.0650). Conclusion: The results of this study indicate that SK-7041 has a radiosensitizing effect for the RIF-1 cell line in vivo at a low concentration and this effect may be synergistic. Implementing this result to clinical trial is warranted.

목적: 국내에서 합성된 히스톤 탈아세틸 효소 억제제인 SK-7041의 생체내 방사선 감수성 증진 효과를 확인하고자 하였다. 대상 및 방법: 6주령의 웅형 C3H 마우스에 RIF-1 세포를 주입한 후 대조군 약물군 방사선군, 방사선 및 약물군으로 분류하였다. 약물군과 방사선 및 약물군에는 SK-7041 4 mg/kg을 12시간 간격으로, 6회에 걸쳐 복강 내 투여하였다. 대조군 및 방사선군에는 동일 용량의 phosphate buffered saline (PBS)를 같은 방법으로 투여하였다. 방사선군과 방사선 및 약물군에는 4번째 투약 후 6시간 후에 5 Gy를 1회 조사하였다. 이후 2~3일 간격으로 종양의 크기를 측정하여 종양 성장 연기 곡선을 산출하였다. 결과: 접종된 종양이 $1,500mm^3$까지 자라는 데 소요된 기간은 대조군, 약물군, 방사선군, 방사선 및 약물군에서 각각 10일, 9일, 9일, 12일이고, 14일째의 체적은 각각 $276.7mm^3$, $279.9mm^3$, $292.5mm^3$, $185.5mm^3$로, 각 군간의 차이는 통계학적으로 유의하였다(p=0.0004). 아울러, 대조군과 약물군의 차이와 방사선군과 방사선 및 약물군의 차이를 비교하였을 때, 통계학적으로 유의한 경향을 보였다(p=0.0650). 결론: 히스톤 탈아세틸 효소 억제제인 SK-7041 의 RIF-1 세포주에 대한 마우스내 방사선 감수성 증진 효과를 저농도에서 확인할 수 있었으며, 방사선과 SK-7041의 상호작용은 상승 작용일 가능성을 시사하였다. 향후 환자에서의 적용 가능성에 대한 연구가 필요할 것으로 생각한다.

Keywords

References

  1. De Schutter H, Nuyts S. Radiosensitizing potential of epigenetic anticancer drugs. Anticancer Agents Med Chem 2009:9:99-108 https://doi.org/10.2174/187152009787047707
  2. Kim JH, Shin JH, Chie EK, et al. Trichostatin A, a histone deacetylase inhibitor, potentiated cytotoxic effect of inonizing radiation in human head and neck cancer cell lines. J Korean Soc Ther Radiol Oncol 2004;22:138-144
  3. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;59:1174-1180 https://doi.org/10.1016/j.ijrobp.2004.03.001
  4. Kim IA, Kim JH, Shin JH, et al. A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells. Cancer Res Treat 2005;37:122-128 https://doi.org/10.4143/crt.2005.37.2.122
  5. Kim IA, Kim JH, Shin JH, et al. Leptomycin B increases radiosensitization by trichostatin A in HeLa cells. J Korean Soc Ther Radiol Oncol 2005;23:116-122
  6. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-4056 https://doi.org/10.1200/JCO.2007.11.6202
  7. Kim DK, Lee JY, Kim JS, et al. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J Med Chem 2003:46:5745-5751 https://doi.org/10.1021/jm030377q
  8. Park JH, Jung Y, Kim TY, et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004;10:5271-5281 https://doi.org/10.1158/1078-0432.CCR-03-0709
  9. Kim BK. Radiosensitizing effect and mechanisms of action of a novel HDAC inhibitor, SK-7041 [dissertation]. Seoul: Seoul National University, 2007
  10. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116 https://doi.org/10.1038/nrc1799
  11. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006;94:179-183 https://doi.org/10.1038/sj.bjc.6602918
  12. Lee KW, Kim JH, Park JH, et al. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 2006;26:3429-3438
  13. Ryu JK, Lee WJ, Lee KH, et al. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 2006;237:143-154 https://doi.org/10.1016/j.canlet.2005.05.040
  14. Camphausen K, Scott T, Sproull M, Tofilon PJ. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004;10:6066-6071 https://doi.org/10.1158/1078-0432.CCR-04-0537
  15. Chung YL, Wang AJ, Yao LF. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 2004;3:317-325 https://doi.org/10.4161/cbt.3.3.698
  16. Paoluzzi L, Figg WD. Histone deacetylase Inhibitors are potent radiation protectants. Cancer Biol Ther 2004;3:612-613 https://doi.org/10.4161/cbt.3.7.931
  17. Purrucker JC, Fricke A, Ong MF, Rube C, Rube CE, Mahlknecht U. HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. Oncol Rep 2010;23:263-269
  18. Coyle TE, Bair AK, Stein C, Vajpayee N, Mehdi S, Wright J. Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? Am J Hematol 2005;78:256-260 https://doi.org/10.1002/ajh.20273

Cited by

  1. Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells vol.44, pp.1, 2010, https://doi.org/10.14407/jrpr.2019.44.1.15